Curaleaf Reports Fourth Quarter and Fiscal Year End 2021 Results

- Record fiscal year 2021 revenue and Adjusted EBITDA ⁽¹⁾ of $1.2 billion and $298 million , representing an increase of 93% and 107%, respectively

- Fourth quarter 2021 Revenue and Adjusted EBITDA of $320 million and $80 million , representing an increase of 39% and 48% year-over-year, respectively

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company") , a leading international provider of consumer products in cannabis, today reported its financial and operating results for the fourth quarter and year ended December 31, 2021 . All financial information is provided in U.S. dollars unless otherwise indicated.

Fourth Quarter and FY 2021 Financial Highlights (Unaudited)
($ thousands, except per share amounts)	Q4 2021	Q4 2020 (As Restated)	% yoy Change	FY 2021	FY 2020 ( As Restated)	% yoy Change
Total Revenue	$320,011	$230,253	39%	$1,209,661	$626,637	93%
Gross profit before impact of biological assets	159,437	110,595	44%	588,051	315,489	86%
Gross profit on cannabis sales ⁽¹⁾⁽²⁾	158,809	109,625	45%	585,734	275,071	113%
Gross margin on cannabis sales ⁽¹⁾⁽²⁾	49.7%	47.8%		48.5%	46.9%
Adjusted EBITDA ⁽¹⁾⁽²⁾	79,675	53,784	48%	298,037	144,080	107%
Net loss attributable to Curaleaf Holdings Inc.	(27,543)	(37,067)		(101,731)	(57,161)
Net loss per share – basic and diluted	($0.04)	($0.06)		($0.15)	($0.10)


(1)	Represents a Non-IFRS financial measure or Non-IFRS ratio without a standardized definition under IFRS, which may not be comparable to similar measures used by other issuers.
(2)	See "Non-IFRS Financial and Performance Measures" below for definitions and more information regarding Curaleaf's use of Non-IFRS financial measures and Non-IFRS ratios. See the sections entitled "Gross Profit on Cannabis Sales" and "Adjusted EBITDA" below (pgs. 3-7) for reconciliations of Non-IFRS measures to the most directly comparable IFRS measures.
(3)	Cannabis sales excludes Management Fee Income. Gross profit and gross margin on cannabis sales both exclude the impact of biological assets.

Earnings Call: Thursday, March 3, 2022 , at 5:00 P.M. ET
Conference ID # is 1618049
Replay ID # is 4919700

U.S. Live Call: +1-888-317-6003
International Live Call (Toll): +1-412-317-6061
Canada Live Call: +1-866-284-3684

U.S. Replay: +1-877-344-7529
International Replay (Toll): +1-412-317-0088
Canada Replay: +1-855-669-9658

A webcast of the call can be accessed on the investor relations section of the Curaleaf website at ir.curaleaf.com
The teleconference will be available for replay starting at approximately 7:00 P.M. ET on March 3, 2022 , and will end at 7:00 P.M. ET on March 10, 2022

Boris Jordan , Executive Chairman of Curaleaf, commented, "2021 was another exceptional year for Curaleaf. We reached a significant milestone by generating over 90% revenue growth and exceeding $1.2 billion of total revenue for the first time. We continued to deliver gross and Adjusted EBITDA margin expansion and ended the year with one of the strongest balance sheets in the industry to support our ongoing growth strategies. In addition, we announced strategic acquisitions that have strengthened our ability to continue gaining share in key U.S. markets as well as internationally. Looking to 2022, we remain focused on executing our plan for strong, above market revenue growth and margin accretion, and believe we are incredibly well positioned to benefit from significant near-term catalysts such as the anticipated launch of New Jersey's adult use market."

Joe Bayern , Chief Executive Officer of Curaleaf, stated, "In 2021, we made significant progress strengthening all areas of our business including growing our retail and wholesale distribution, introducing new products, expanding our cultivation and production capacity, and entering new markets such as Europe . I believe our focus and strong execution in 2021 set us up extraordinarily well for the significant growth opportunities that lie ahead in 2022 and beyond. I am incredibly proud of the hard work and dedication of all our team members who have made our continued success possible. I believe Curaleaf is better positioned than ever to capitalize on the massive and growing cannabis opportunity."

Fourth Quarter 2021 Operating Highlights

Added eight new retail dispensaries including five in Florida , two in Colorado , and one in Arizona .
Entered into a definitive agreement to acquire Tryke Companies, a vertically integrated MSO in Nevada , Arizona , and Utah .
Entered into a definitive agreement to acquire Natural Remedy Patient Center, LLC, a Safford, Arizona dispensary.
Entered into a definitive agreement to acquire Bloom Dispensaries, a single state operator in Arizona .
Completed the offering of $475 million aggregate principal amount of 8.0% Senior Secured Notes due 2026 and retired all prior indebtedness, increasing liquidity and materially reducing the average interest rate on the Company's outstanding debt.
Signed a national distribution agreement with Southern Glazer's Wine & Spirits to bring Curaleaf's Hemp and Select CBD product lines into Southern Glazer's distribution network.

Full Year 2021 Operating Highlights

Significantly expanded retail, wholesale, and cultivation operations through organic growth and strategic acquisitions.

Increased retail locations from 96 to 117 as of December 31, 2021 .
Reached approximately 2,300 active wholesale accounts as of December 31, 2021 , an increase of over 90% from year end 2020.
Grew cultivation sites from 23 to 25.
Expanded total cultivation and production capacity by over 2.5 million square feet to approximately 4.4 million square feet.

Significant focus on R&D activities drove the introduction of 147 new products in our markets, with approximately 11% of full year 2021 revenue generated by new products launched in the last 12 months.
Entered the European market through the successful acquisition of EMMAC Life Sciences Group and subsequently rebranded to Curaleaf International.
Completed the acquisition of Los Sueños Farms, the largest outdoor grow in Colorado .

Post Fourth Quarter 2021 Highlights

Completed the acquisition of Bloom Dispensaries adding four retail locations and two cultivation and processing facilities totaling 63,500 square feet in Arizona .
Continued to organically expand our retail footprint, opening two additional dispensaries in Florida and three in Pennsylvania . As of March 3, 2022 , Curaleaf retail operations totaled 126 nationwide.

Financial Results for the Fourth Quarter Ended December 31, 2021

Revenue (Unaudited)
($ thousands)
	Q4 2021	Q3 2021	Q4 2020
Retail revenue	$225,592	$224,543	$164,932
Wholesale revenue	93,791	92,041	64,351
Management fee income	628	541	970
Total Revenue	$320,011	$317,125	$230,253

Total revenue was a record $320 million for the fourth quarter of 2021, an increase of 1% from $317 million in the third quarter of 2021 and 39% from $230 million in the fourth quarter of 2020. The Company's year-over-year revenue growth primarily reflects continued organic growth driven by new retail store openings, the addition of new wholesale partner accounts, product launches, and the expansion of cultivation and production facilities.

Retail revenue was $226 million , compared with $225 million in the third quarter of 2021, and up 37% from $165 million in the fourth quarter of 2020. Retail revenue represented 71% of total revenue. Curaleaf's year-over-year retail revenue growth was supported by 21 new stores added in 2021.

Wholesale revenue was $94 million , an increase of 2% from the third quarter of 2021 and 46% year-over-year and represented 29% of total revenue. Wholesale revenue growth was supported by the addition of new wholesale partner accounts, which increased by more than 90% from year-end 2020 to approximately 2,300 total accounts.

Gross Profit on Cannabis Sales (Unaudited)
($ thousands)
	Q4 2021	Q3 2021	Q4 2020
Retail and wholesale revenue	$319,383	$316,584	$229,283
Cost of goods sold	160,574	172,216	119,658
Gross profit on cannabis sales ⁽¹⁾	158,809	144,368	109,625
Gross margin on cannabis sales ⁽¹⁾	49.7%	45.6%	47.8%
Management fee income ⁽²⁾	628	541	970
Gross profit before impact of biological assets	$159,437	$144,909	$110,595


(1)	Represents a non-IFRS measure or Non-IFRS ratio. See "Non-IFRS Financial and Performance Measures" below for definitions and more information regarding Curaleaf's use of Non-IFRS financial measures and Non-IFRS ratios.
(2)	Management fee income is added to Gross Profit on Cannabis Sales to obtain Gross profit before impact of biological assets, the most comparable IFRS measure.

Gross profit on cannabis sales was $159 million for the fourth quarter of 2021, an increase of 10% from $144 million in the third quarter of 2021 and 45% from $110 million in the fourth quarter of 2020. Gross profit margin was 49.7%, an increase of approximately 410 basis points from the prior quarter and 190 basis points from the fourth quarter of 2020. The increase in gross margin reflects continued efficiency in the Company's cultivation and processing facilities and improving economies of scale. In addition, the sequential increase in gross margin partially reflects a loss on inventory related to the Eureka, California facility divestiture and the write down of certain other inventory in the third quarter of 2021, which did not recur.

Net Income / (Loss) (Unaudited)
($ thousands)
	Q4 2021	Q3 2021	Q4 2020
		(As Restated)	(As Restated)
Total Revenue	$320,011	$317,125	$230,253
Gross profit	179,546	182,734	125,462
Income (Loss) from operations	42,875	42,381	23,013
Total other income (expense), net	(32,649)	(38,955)	(17,893)
Income tax benefit (expense)	(40,281)	(60,313)	(42,022)
Net loss	(30,055)	(56,887)	(36,902)
Less: Net loss attributable to non-controlling interest	(2,512)	(2,363)	165
Net loss attributable to Curaleaf Holdings, Inc.	($27,543)	($54,524)	($37,067)

Net loss attributable to Curaleaf Holdings, Inc. was $28 million , compared with a net loss of $55 million in the third quarter of 2021 and $37 million in the fourth quarter of 2020. The year-over-year improvement in net loss was primarily driven by an approximately $20 million increase in operating income and $2 million of lower income tax expense, partially offset by $15 million of higher other expense, net.

Adjusted EBITDA (Unaudited)
($ thousands)
	Q4 2021	Q3 2021	Q4 2020
		(As Restated)	(As Restated)
Net loss	($30,055)	($56,887)	($36,902)
Interest expense, net	22,626	25,054	25,366
Income tax expense	40,281	60,313	42,022
Depreciation and amortization ⁽¹⁾	37,507	34,739	26,647
Share-based compensation	9,175	13,180	16,114
Other (income) expense	10,023	13,900	(7,473)
Change in fair value of biological assets	(20,109)	(37,825)	(14,866)
Other add-backs ⁽²⁾	10,227	18,889	2,876
Adjusted EBITDA ⁽³⁾	$79,675	$71,363	$53,784
Adjusted EBITDA Margin ⁽³⁾	24.9%	22.5%	23.5%


(1)	Depreciation and amortization expense in Q4 2021, Q3 2021, and Q4 2020 include amounts charged to cost of goods sold on the statement of profits and losses.
(2)	Other add-backs in Q4 2021 primarily include acquisition related expenses, legal fees, and accounting and professional fees.
(3)	Represents a non-IFRS measure or Non-IFRS ratio. See "Non-IFRS Financial and Performance Measures" below for definitions and more information regarding Curaleaf's use of Non-IFRS financial measures and Non-IFRS ratios. The table above provides a reconciliation of Net Loss, the most comparable IFRS measure, to Adjusted EBITDA, a non-IFRS measure.

Adjusted EBITDA was $80 million for the fourth quarter of 2021, an increase of 12% from $71 million in the third quarter of 2021 and 48% from $54 million in the fourth quarter of 2020. Adjusted EBITDA margin was 24.9%, an increase of 240 basis points from 22.5% in the prior quarter and 140 basis points from 23.5% in the fourth quarter of 2020. The sequential increase in Adjusted EBITDA primarily reflects higher gross profit margin driven by continued efficiency in the Company's cultivation and processing facilities and improving economies of scale. On a year-over-year basis, the increases in Adjusted EBITDA and Adjusted EBITDA margin primarily reflect higher revenue and gross profit margin partially offset by higher SG&A expense related to increased headcount ahead of new store openings and marketing in support of new product rollouts.

Financial Results for the Year Ended December 31, 2021
Revenue (Unaudited)
($ thousands)
	FY 2021	FY 2020
Retail revenue	$859,959	$423,183
Wholesale revenue	347,385	163,036
Management fee income	2,317	40,418
Total Revenue	$1,209,661	$626,637

Total revenue for the year ended 2021 was a record $1,210 million , an increase of 93% from $627 million for the year ended 2020.

Retail revenue was $860 million for the year ended 2021, an increase of 103% from $423 million for the year ended 2020. The increase in retail revenue was primarily driven by organic growth from new store openings, expansion of cultivation and production capacity, and new product introductions. Retail revenue growth in 2021 also reflects a full year of revenue recognized from the Company's acquisition of GR Companies, Inc. ("Grassroots"), which closed in July 2020 , and to a lesser extent, the partial year benefit of the acquisitions of EMMAC Life Sciences Limited ("EMMAC") in August 2021 and Los Sueños Farms and related entities ("Los Sueños") in October 2021 .

Wholesale revenue was $347 million , an increase of 113% from $163 million for the year ended 2020. Growth in wholesale revenue was primarily due to organic growth from wholesale partner account additions, new product introductions such as Select Squeeze, Select Fresh, Clique by Select, and Select Snooze Bites, and increased cultivation and production capacity. Wholesale revenue growth also reflected the above-mentioned acquisitions of Grassroots, EMMAC and Los Sueños.

Gross Profit on Cannabis Sales (Unaudited)
($ thousands)
	FY 2021	FY 2020
Retail and wholesale revenue	$1,207,344	$586,219
Cost of goods sold	621,610	311,148
Gross profit on cannabis sales ⁽¹⁾	585,734	275,071
Gross margin on cannabis sales ⁽¹⁾	48.5%	46.9%
Management fee income ⁽²⁾	2,317	40,418
Gross profit before impact of biological assets	$588,051	$315,489


(1)	Represents a non-IFRS measure or Non-IFRS ratio. See "Non-IFRS Financial and Performance Measures" below for definitions and more information regarding Curaleaf's use of Non-IFRS financial measures and Non-IFRS ratios.
(2)	Management fee income is added to Gross Profit on Cannabis Sales to obtain Gross profit before impact of biological assets, the most comparable IFRS measure.

Gross profit on cannabis sales was $586 million for the year ended 2021, an increase of 113% from $275 million in 2020. Gross profit margin was 48.5% an increase of approximately 160 basis points from 46.9% in 2020. The increases in gross profit and gross margin were primarily driven by revenue growth and the continued improvement in the operating capacity and efficiency of the Company's cultivation and processing facilities.

Net Income / (Loss) (Unaudited)
($ thousands)
	FY 2021	FY 2020
		(As Restated)
Total Revenue	$1,209,661	$626,637
Gross profit	687,589	390,513
Income (Loss) from operations	175,634	72,437
Total other income (expense), net	(110,838)	(41,641)
Income tax benefit (expense)	(173,926)	(87,550)
Net loss	(109,130)	(56,754)
Less: Net loss attributable to non-controlling interest	(7,399)	407
Net loss attributable to Curaleaf Holdings, Inc.	($101,731)	($57,161)

Net loss, attributable to Curaleaf Holdings, Inc., for the year ended 2021 was $102 million , compared with a net loss of $57 million for the year ended 2020. The $103 million increase in operating income in 2021 was offset primarily by $69 million of higher total other expense, net, and $86 million of higher income tax expense. The year-over-year increase in total other expense, net, was primarily due to an approximately $38 million gain on investment in 2020 that did not recur, $27 million of higher interest expense net of interest income, and $11 million of higher other expenses, partially offset by $9 million of lower impairment charges on intangible assets.

Adjusted EBITDA (Unaudited)
($ thousands)
	FY 2021	FY 2020
		(As Restated)
Net loss	($109,130)	($56,754)
Interest expense, net	89,633	62,518
Income tax expense	173,926	87,550
Depreciation and amortization ⁽¹⁾	132,644	79,713
Share-based compensation	45,632	30,879
Other (income) expense	21,205	(20,877)
Change in fair value of biological assets	(99,538)	(75,024)
Other add-backs ⁽²⁾	43,665	36,075
Adjusted EBITDA ⁽³⁾	$298,037	$144,080
Adjusted EBITDA Margin ⁽³⁾	24.6%	23.0%


(1)	Depreciation and amortization expense in 2021 and 2020 include amounts charged to cost of goods sold on the statement of profits and losses.
(2)	Other add-backs in 2021 primarily include acquisition related expenses, accounting and professional fees, legal fees, bad debt write off, employee severance costs, one-time loss on inventory related to a California facility divestiture, and inventory write-down in one of our states.
(3)	Represents a non-IFRS measure or Non-IFRS ratio. See "Non-IFRS Financial and Performance Measures" below for definitions and more information regarding Curaleaf's use of Non-IFRS financial measures and Non-IFRS ratios. The table above provides a reconciliation of Net Loss, the most comparable IFRS measure, to Adjusted EBITDA, a non-IFRS measure.

Adjusted EBITDA for the year ended 2021 was $298 million , an increase of 107% from $144 million in 2020. Adjusted EBITDA margin was 24.6%, an increase of 160 basis points from 23.0% in the prior year. The increases in Adjusted EBITDA and Adjusted EBITDA margin primarily reflect higher revenue and gross profit margin partially offset by higher SG&A expense related to increased headcount in support of new store openings and marketing in support of new product rollouts.

Balance Sheet and Cash Flow

As of December 31, 2021 , the Company had $299 million of cash and $436 million of outstanding debt net of unamortized debt discounts.

During the fourth quarter of 2021, Curaleaf invested $55 million , net in capital expenditures, focused on cultivation, processing, and selective retail expansion in strategic markets. For the year ended 2021, Curaleaf invested $172 million , net in capital expenditures.

Shares Outstanding

As of December 31, 2021 , and September 30, 2021 , the Company's weighted average subordinate voting shares outstanding amounted to 707,450,310 and 703,545,262 shares, respectively.

As of December 31, 2021 , and September 30, 2021 , Company's issued and outstanding subordinate voting shares plus multiple voting shares amounted to 708,340,434 and 704,818,302 shares, respectively.

Other

The Company has made an immaterial restatement to the initial purchase accounting for the Select acquisition. Adjustments have been made to all of the comparative period financial statements presented herein, which reflect a decrease in intangible assets, deferred tax liability, and amortization expense, as well as an increase in goodwill and income tax expense, as applicable. The net impact of these adjustments on the Company's Consolidated Statements of Profits and Losses for the year ended December 31, 2020 , was a positive $4.6 million to Net loss attributable to Curaleaf Holdings, Inc. Additional detail will be provided in the Company's Consolidated Annual Financial Statements.

Non-IFRS Financial and Performance Measures

Curaleaf reports its financial results in accordance with IFRS and uses a number of financial measures and ratios when assessing its results and measuring overall performance. Some of these financial measures and ratios are not calculated in accordance with IFRS. Curaleaf refers to certain Non-IFRS financial measures and ratios such as "Gross Profit on Cannabis Sales", "Gross Margin on Cannabis Sales", "Adjusted EBITDA", and "Adjusted EBITDA Margin". These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. The Company defines "Gross Profit on Cannabis Sales" as retail and wholesale revenues less cost of goods sold. "Gross Margin on Cannabis Sales" is defined by Curaleaf as gross profit on cannabis sales divided by retail and wholesale revenues. "Adjusted EBITDA" is defined by Curaleaf as earnings before interest, taxes, depreciation and amortization less share-based compensation expense and other add-backs related to business development, acquisition, financing and reorganization costs. "Adjusted EBITDA Margin" is defined by Curaleaf as Adjusted EBITDA divided by total revenue. Curaleaf considers these measures to be an important indicator of the financial strength and performance of our business. We believe the adjusted results presented provide relevant and useful information for investors because they clarify our actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since these measures are not calculated in accordance with IFRS, they should not be considered in isolation of, or as a substitute for, our reported results as indicators of our performance, and they may not be comparable to similarly named measures from other companies. The tables provided in this press release contained in the sections "Gross Profit on Cannabis Sales" and "Adjusted EBITDA" (pgs. 3-7) provide reconciliations of Non-IFRS measures to the most directly comparable IFRS measures.

Consolidated Statements of Financial Position (Unaudited)
($ thousands)
	December 31,		December 31,
	2021		2020
				(As Restated)
Assets
Current assets:
Cash	$	299,329	$	73,542
Accounts receivable		64,570		28,830
Inventory, net		391,195		197,991
Biological assets		78,600		46,210
Assets held for sale		80,583		58,504
Prepaid expenses and other current assets		35,667		10,140
Current portion of notes receivable		2,315		2,645
Total current assets		952,259		417,862
Deferred tax asset		2,593		5,528
Notes receivable		842		2,000
Property, plant and equipment, net		379,720		242,855
Right-of-use assets, net		285,111		267,168
Intangible assets, net		1,010,008		707,634
Goodwill		605,496		538,825
Investments		4,401		16,264
Prepaid acquisition consideration		—		132,234
Other assets		22,048		35,135
Total assets	$	3,262,478	$	2,365,505

Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable	$	26,751	$	47,043
Accrued expenses		87,583		57,475
Income tax payable		140,019		79,649
Current portion of lease liability		19,279		15,710
Current portion of notes payable		1,966		6,500
Current contingent consideration liability		9,155		—
Liabilities held for sale		18,472		7,181
Other current liabilities		12,171		6,568
Total current liabilities		315,396		220,126
Deferred tax liability		299,333		200,805
Notes payable		434,123		285,001
Lease Liabilities		298,281		270,495
Non-controlling interest redemption liability		72,140		2,694
Contingent consideration liability		28,839		1,898
Other long term liability		5,876		3,698
Total liabilities		1,453,988		984,717

Shareholders' equity:
Share capital		2,225,940		1,754,412
Treasury shares		(5,208)		(5,208)
Reserves		(162,085)		(177,744)
Accumulated other comprehensive income (deficit)		(9,996)		—
Accumulated deficit		(291,395)		(190,071)
Redeemable non-controlling interest		(72,140)		(2,694)
Total Curaleaf Holdings, Inc. shareholders' equity		1,685,116		1,378,695
Non-controlling interest		123,374		2,093
Total shareholders' equity		1,808,490		1,380,788
Total liabilities and shareholders' equity	$	3,262,478	$	2,365,505

Consolidated Statements of Profits and Losses (Unaudited)
($ thousands, except for share and per share amounts)
	Three Months Ended
	December 31,
	2021		2020
				(As Restated)
Revenue:
Retail and wholesale revenue	$	319,383	$	229,283
Management fee income		628		970
Total revenue		320,011		230,253
Cost of goods sold		160,574		119,658
Gross profit before impact of biological assets		159,437		110,595
Realized fair value amounts included in inventory sold		(102,234)		(57,265)
Unrealized fair value gain on growth of biological assets		122,343		72,132
Gross profit		179,546		125,462
Operating expenses:
Selling, general and administrative		100,257		68,289
Share-based compensation		9,175		16,114
Depreciation and amortization		27,239		18,046
Total operating expenses		136,671		102,449
Income (Loss) from operations		42,875		23,013
Other income (expense):
Interest income		134		24
Interest expense		(13,470)		(13,695)
Interest expense related to lease liabilities		(9,290)		(11,695)
Gain on investment		(2,807)		26,954
Impairment of intangible assets		(8,901)		(23,659)
Other income (expense)		1,685		4,178
Total other income (expense), net		(32,649)		(17,893)
Income (Loss) before provision for income taxes		10,226		5,120
Income tax benefit (expense)		(40,281)		(42,022)
Net loss		(30,055)		(36,902)
Less: Net income (loss) attributable to non-controlling interest		(2,512)		165
Net loss attributable to Curaleaf Holdings, Inc.	$	(27,543)	$	(37,067)
Loss per share attributable to Curaleaf Holdings, Inc. – basic and diluted	$	(0.04)	$	(0.06)
Weighted average common shares outstanding – basic and diluted		707,450,310		660,398,593

Consolidated Statements of Profits and Losses (Unaudited)
($ thousands, except for share and per share amounts)
	Twelve Months Ended
	December 31,
	2021		2020
				(As Restated)
Revenue:
Retail and wholesale revenue	$	1,207,344	$	586,219
Management fee income		2,317		40,418
Total revenue		1,209,661		626,637
Cost of goods sold		621,610		311,148
Gross profit before impact of biological assets		588,051		315,489
Realized fair value amounts included in inventory sold		(365,642)		(149,586)
Unrealized fair value gain on growth of biological assets		465,180		224,610
Gross profit		687,589		390,513
Operating expenses:
Selling, general and administrative		370,106		227,274
Share-based compensation		45,632		30,879
Depreciation and amortization		96,217		59,923
Total operating expenses		511,955		318,076
Income (Loss) from operations		175,634		72,437
Other income (expense):
Interest income		629		6,484
Interest expense		(53,549)		(47,903)
Interest expense related to lease liabilities		(36,713)		(21,099)
Gain on investment		(2,974)		37,560
Impairment of intangible assets		(14,573)		(23,659)
Other income (expense)		(3,658)		6,976
Total other income (expense), net		(110,838)		(41,641)
Income (Loss) before provision for income taxes		64,796		30,796
Income tax benefit (expense)		(173,926)		(87,550)
Net loss		(109,130)		(56,754)
Less: Net income (loss) attributable to non-controlling interest		(7,399)		407
Net loss attributable to Curaleaf Holdings, Inc.	$	(101,731)	$	(57,161)
Loss per share attributable to Curaleaf Holdings, Inc. – basic and diluted	$	(0.15)	$	(0.10)
Weighted average common shares outstanding – basic and diluted		698,759,274		557,192,899

Consolidated Statements of Cash Flows (Unaudited)
($ thousands, except for share and per share amounts)
	Twelve Months Ended
	December 31,
	2021		2020
				(As Restated)
Cash flows from operating activities:
Net loss	$	(109,130)		(56,754)
Adjustments to reconcile loss to net cash provided (used) in operating activities:
Depreciation and amortization		132,644		79,713
Share-based compensation		45,632		29,361
Non-cash Bonus		—		1,518
Non-cash interest expense		44,859		6,590
Unrealized gain on changes in fair value of biological assets		(465,180)		(224,610)
Realized fair value amounts included in inventory sold		365,642		149,586
Impairment loss		14,573		23,659
(Gain)/loss on debt retirement		152		—
(Gain)/loss on investment		2,974		—
(Gain)/loss on sale of property, plant and equipment		3,333		550
Deferred taxes		19,214		11,720
Gain on contingent liability		—		(37,566)
Changes in operating assets and liabilities
Accounts receivable		(29,402)		5,956
Biological assets		80,414		55,707
Inventories		(185,607)		(92,384)
Prepaid expenses and other current assets		(24,902)		4,748
Other assets		5,641		(17,702)
Accounts payable		(10,298)		9,958
Income taxes payable		59,768		57,753
Accrued expenses		15,709		4,552
Net cash provided by (used in) operating activities		(33,964)		12,355
Cash flows from investing activities:
Purchases of property, plant and equipment, net		(171,955)		(126,273)
Proceeds from sale of entity		29,828		1,004
Payments made on completion on acquisitions		(37,820)		(59,695)
Prepayment of acquisition consideration		—		(7,500)
Cash acquired from acquisitions		14,500		—
Payments received on notes receivable		3,717		(4,646)
Note receivable from third party		(2,244)		—
Net cash used in investing activities		(163,974)		(197,110)
Cash flows from financing activities:
Cash received from financing agreement		531,093		186,235
Proceeds from sale leaseback		24,419		42,466
Debt issuance costs		(5,564)		—
Minority buyouts		(1,190)		(2,508)
Lease liability payments		(52,775)		(26,762)
Proceeds from minority interest investment in Curaleaf International		83,979		—
Cash received in private placement		—		24,552
Prepayment penalties on retired notes payable		(23,827)		—
Principal payments on notes payable		(366,749)		(2,920)
Acquisition escrow shares returned and retired		(8,312)		—
Exercise of stock options		3,157		3,013
Issuance of common shares, net of issuance costs		240,569		—
Net cash provided by financing activities		424,800		224,076
Net change in cash		226,862		39,321
Cash at beginning of period		73,542		42,310
Cash held for sale		—		(8,089)
Effect of exchange rate on cash		(1,075)		—
Cash at end of period	$	299,329	$	73,542

About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States , Curaleaf currently operates in 23 states with 126 dispensaries, 26 cultivation sites, and employs over 5,600 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com .

Curaleaf IR Twitter Account	https://twitter.com/Curaleaf_IR

Investor Toolkit	https://ir.curaleaf.com/investor-toolkit

Investor Relations Website	https://ir.curaleaf.com/

Contact Information
	Investor Contact:
	Curaleaf Holdings, Inc.
	Carlos Madrazo, SVP Head of IR & Capital Markets
	ir@curaleaf.com

	Media Contact:
	Curaleaf Holdings, Inc.
	Tracy Brady, VP of Corporate Communications
	media@curaleaf.com

Disclaimer

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of Canadian securities laws and United States securities laws ("forward-looking statements"). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current beliefs, expectations or assumptions regarding the future of the business, plans and strategies, operational results and other future conditions of the Company. In addition, the Company may make or approve certain statements in future filings with Canadian securities regulatory authorities, in press releases, or in oral or written presentations by representatives of the Company that are not statements of historical fact and may also constitute forward-looking statements. All statements, other than statements of historical fact, made by the Company that address activities, events or developments that the Company expects or anticipates will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as "assumptions", "assumes", "guidance", "outlook", "may", "will", "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "plans", "intends", "anticipates", "targeted", "continues", "forecasts", "designed", "goal", or the negative of those words or other similar or comparable words and includes, among others, information regarding: its outlook for and expected operating margins, capital allocation, free flow cash and other financial results; growth of its operations via expansion, for the effects of any transactions; expectations for the potential benefits of any transactions; statements relating to the business and future activities of, and developments related to, the Company after the date of this press release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's business, operations and plans; expectations that planned acquisitions will be completed; expectations regarding cultivation and manufacturing capacity; expectations regarding receipt of regulatory approvals; expectations that licenses applied for will be obtained; potential future legalization of adult-use and/or medical cannabis under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future. Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the available funds of the Company and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the cannabis industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to contracts with third-party service providers; risks related to the enforceability of contracts; reliance on the expertise and judgment of senior management of the Company, and ability to retain such senior management; risks related to proprietary intellectual property and potential infringement by third-parties; the concentrated voting control of the Company's Chairman and the unpredictability caused by the capital structure; risks relating to the management of growth; increasing competition in the industry; risks inherent in an agricultural business; risks relating to energy costs; risks associated to cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; cybersecurity risks; ability and constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada ; risks related to future acquisitions or dispositions; sales by existing shareholders; limited research and data relating to cannabis; as well as those risk factors discussed under "Risk Factors" in the Company's Annual Management, Discussion and Analysis dated March 11, 2021 , and in the Company's Annual Information Form dated April 28, 2021 (both of which documents have been filed on the Company's SEDAR profile at www.sedar.com and on its EDGAR profile at www.sec.gov/edgar/html ) and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. The purpose of forward-looking statements is to provide the reader with a description of management's expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this press release as well as statements regarding the Company's objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. You should not place undue reliance on forward-looking statements contained in this press release. Such forward-looking statements are made as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company's forward-looking statements are expressly qualified in their entirety by this cautionary statement.

This press release contains future-oriented financial information and financial outlook information (collectively, "FOFI") about the Company's prospective results of operations, production and production efficiency, commercialization, revenue and cash on hand, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set second in the above paragraph. FOFI contained in this document was approved by management as of the date of this document and was provided for the purpose of providing further information about the Company's future business operations. The Company disclaims any intention or obligation to update or revise any FOFI contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein. The financial information reported in this press release is based on management prepared financial statements for the quarter and year ended December 31, 2021 . Accordingly, such financial information may be subject to change. Financial statements for the period will be released and filed under the Company's profiles on SEDAR at www.sedar.com no later than March 11, 2022 . All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company's financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company's financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this press release.

View original content: https://www.prnewswire.com/news-releases/curaleaf-reports-fourth-quarter-and-fiscal-year-end-2021-results-301495401.html

SOURCE Curaleaf Holdings, Inc.

News Provided by PR Newswire via QuoteMedia

cannabis investing cura:cnx

CURA:CNX,CURLF

Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve.

Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among younger users, and cannabis companies are adapting their offerings to meet shifting demand.

Meanwhile, regulatory uncertainty, particularly surrounding the future of the US Farm Bill and state-level restrictions on hemp-derived cannabinoids, continues to challenge the market.

Despite these headwinds, production data and long-term growth forecasts suggest the cannabis industry remains on a promising — albeit turbulent — path. Read on for more on key trends to watch in 2025.

Consumption methods evolving post-legalization

Shifts in consumer behavior are reshaping markets across the board, and the cannabis industry is no exception.

While smoking remains the dominant method of cannabis consumption, a recent report from the Centers for Disease Control and Prevention highlights the growing popularity of edibles, vaping and dabbing.

The report notes that vaping and dabbing are particularly pronounced among younger adults.

A separate study published by the American Medical Association and funded in part by the Canadian Institutes of Health Research also points to how product preferences have changed among Canadian users since legalization in 2018.

The study indicates that while the use of flower, cannabis concentrates, oil, tinctures and topicals has decreased during that time, the use of vape cartridges, edibles and beverages has increased.

Edibles and beverages were legalized in Canada in late 2019, and Truss Beverage was one of the first players to introduce cannabis-infused drinks. Truss was a joint venture formed by Molson Coors Canada (TSX:TPX.A,TSX:TPX.B) and HEXO, a cannabis company that has since been acquired by Tilray Brands (TSX:TLRY,NASDAQ:TLRY).

In early 2020, Tilray launched a lineup of confectionery, wellness products and beverages through its subsidiary, High Park; Canopy Growth (TSX:WEED,NASDAQ:CGC) made a similar move. These companies gradually brought their products to the US as more states legalized cannabis for medical and/or recreational use.

Today, established cannabis brands typically offer edibles and beverages alongside their other products. Organigram Global (TSX:OGI,NASDAQ:OGI) is one of the newest US entrants, with its April acquisition of Collective Project providing immediate access to the US hemp-derived THC beverage market.

Growing awareness of health and wellness, potentially amplified by the pandemic-led adoption of health trackers, appears to be making an impact on the alcoholic beverage market.

A 2023 Gallup poll reveals a two decade decline in alcohol consumption, particularly among younger adults, suggesting a shift towards more health-conscious lifestyles within this demographic.

Craft beer production declined by 4 percent year-on-year in 2024, according to data collected by the Brewers Association. This marked the largest drop in the industry's history, excluding the pandemic. For small, independent craft breweries, 2024 marked the third consecutive year of declining production. A drop in the number of operating small breweries last year provides further evidence of this trend, with 501 closures in 2024 versus 434 openings.

Challenges in the alcohol market extend beyond the brewing industry, with the New York Times recently reporting the closure of a handful of nightclubs facing decreased alcohol sales alongside rising insurance and rent costs.

Meanwhile, cannabis lounges have been popping up across the US for the last several years. As of early 2025, several states had legalized or were in the process of implementing regulations for cannabis consumption lounges.

Hemp market growth despite regulatory uncertainty

The burgeoning hemp industry is another segment of the expanding cannabis market.

The legalization of industrial hemp — defined as cannabis with a THC concentration of 0.3 percent or less — through the 2018 Farm Bill led to initial investment and optimistic projections for CBD wellness products and various industrial applications. The sector’s rapid evolution also brought the rise of hemp-derived intoxicating cannabinoids, creating a market that presented both opportunities and complexities for participants.

However, after an initial boom, a lack of infrastructure and clearly defined regulations for CBD, as well as state-level variations and market oversupply, ultimately contributed to a quick retraction.

2024 was a pivotal year for the US hemp industry, as the hemp-related provisions of the 2018 Farm Bill — originally set to expire in September 2023, but extended to December 31, 2024 — created an urgent need to address critical issues like THC limits and the regulation of novel hemp-derived cannabinoids. A major point of contention was the proposed shift from defining hemp based on Delta-9 THC concentration (0.3 percent or less) to “total THC,” which includes THCA.

This change had the potential to significantly impact farmers and processors, as many hemp varieties that are compliant under the Delta-9 THC rule could exceed the 0.3 percent limit when THCA is included.

Various bills and amendments were proposed in 2024 as part of the Farm Bill discussions, each with different approaches to regulating hemp. Separate regulatory frameworks for industrial hemp and hemp grown for cannabinoids were suggested, and many states took their own action, leading to a patchwork of regulations and even outright bans.

Despite challenges, data from the US Department of Agriculture suggests signs of recovery.

The department's annual National Hemp Report from 2024 points to an 18 percent increase in industrial hemp production value between 2022 and 2023, with output growth seen in specific sectors like floral (18 percent), fiber (133 percent) and seed hemp (414 percent). The 2025 report from the Department of Agriculture indicates further expansion, with notable increases observed in both acreage (up 64 percent from 2023) and value (46 percent).

The 2024 Farm Bill ultimately did not pass, and right now the hemp industry is operating under a temporary extension of the 2018 Farm Bill under the American Relief Act of 2025, signed into law on December 21, 2024.

The 2018 Farm Bill is now set to expire on September 30, 2025.

While analysts for Markets and Markets project that the North American hemp industry will grow at a CAGR of 22.4 percent and ultimately reach a valuation of US$30.24 billion by 2029, the future of the industry will be heavily influenced by the outcome of the ongoing Farm Bill discussions.

US cannabis legalization remains stalled

Although there is clear demand for cannabis products, the now-defunct rescheduling process in the US is likely to continue casting a shadow of uncertainty over the industry's long-term trajectory.

Legal and procedural delays, including allegations of improper conduct and bias within the US Drug Enforcement Administration (DEA), led to hearing cancellations, and the new administration of US President Donald Trump has brought leadership changes to key agencies like the DEA and the Department of Justice.

Terry Cole, who Trump nominated to be DEA administrator on February 11, has a history of opposing cannabis legalization in the country. Similarly, Pam Bondi, Trump’s pick to lead the justice department, staunchly opposed a movement to legalize medical cannabis during her tenure as Florida’s attorney general.

While there have been bipartisan efforts in Congress to end federal cannabis prohibition and establish regulations for eventual legalization, the DEA’s actions and statements indicate a potential stall or reversal of progress.

In addition to that, new research is adding complexity to the debate.

A study published in the American Journal of Psychiatry this past March highlights an association between the use of high-potency cannabis strains and increased risks of psychosis, a factor that may not have been fully considered by the Department of Health and Human Services. As stronger cannabis strains become more widely available, a reassessment of their potential health risks may be required.

Investor takeaway

While the cannabis industry holds promise for growth and innovation, investors must remain acutely aware of the regulatory uncertainties and market volatility that will undoubtedly shape its trajectory in the years to come.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Curaleaf Reports Fourth Quarter and Fiscal Year End 2021 Results

Economic fallout in Thailand

In this article

Guide to cannabis in Australia: New South Wales

Guide to cannabis in Australia: Victoria

Guide to cannabis in Australia: Queensland

Guide to cannabis in Australia: South Australia

Guide to cannabis in Australia: Western Australia

Guide to cannabis in Australia: Tasmania

Guide to cannabis in Australia: Northern Territory

Guide to cannabis in Australia: Australian Capital Territory

Consumption methods evolving post-legalization

Hemp market growth despite regulatory uncertainty

US cannabis legalization remains stalled

Investor takeaway

1. Botanix Pharmaceuticals (ASX:BOT)

2. Vitura Health (ASX:VIT)

3. IDT Australia (ASX:IDT)

4. Little Green Pharma (ASX:LGP)

5. Neurotech (ASX:NTI)

6. ECS Botanics (ASX:ECS)

7. Cann Group (ASX:CAN)

8. Althea (ASX:AGH)

9. Ecofibre (ASX:EOF)

10. Argent Biopharma (ASX:RGT)

Road to cannabis rescheduling hits another speed bump

Pennsylvania governor proposes legal cannabis market in state budget

Senate committee re-examines the SAFER Banking Act

Aurora, Canopy Growth report earnings

US lawmakers unlikely to prioritize banking reform

Cannabis rescheduling meets delays and controversies

Virginia makes progress on adult-use cannabis

Tilray sees growth across all segments in quarterly results

Latest News

Latest Press Releases

Related News

TOP STOCKS